CRAB has diverse oncology experience by trial phase and has supported 277 hematology/oncology clinical trials.
Clinical Trial Experience
CRAB’s experience in the area of oncology clinical development spans all trial phases (I-IV), tumor types (solid and hematologic), and trial designs. Such diverse therapeutic experience translates into helping each client achieve their own significant objectives. In the same way, CRAB looks forward to developing a strong relationship with HUYA Bioscience International and supporting the HUYA-HBI-8000-103 trial.
The table below highlights CRAB’s diverse oncology experience by trial phase.
| CRAB’s Oncology Trial Experience¹ |
| Trial Phase |
Number of Trials |
% of Trial Experience |
| Phase I |
9 |
3% |
| Phase I / II |
9 |
3% |
| Phase II |
74 |
27% |
| Phase III |
144 |
52% |
| Other² |
41 |
15% |
| Total |
277 |
100% |
1 CRAB's trial experience, in the area of hematology/oncology
2 Other studies include biological correlate, registries, post-marketing, and outcomes research
In addition to our experience across trial phases, we have had exposure to most tumor types in adults, including significant experience in the major disease areas. Our therapeutic experience includes the following:
| • Breast |
• Gynecologic |
• Melanoma |
| • Colorectal |
• Leukemia |
• Myeloma |
| • Gastrointestinal |
• Lung |
• Sarcoma |
| • Genitourinary |
• Lymphoma |
| |
Cancer Staging Experience
CRAB has been an integral collaborator with the International Association for the Study of Lung Cancer (IASLC) since the 1990s, and we will continue this partnership through at least 2016. In 2009, CRAB’s support enabled IASLC to fulfill the objectives of its Lung Cancer Staging Project via submission of evidence-based recommendations for the 7th revision of the tumor, node, and metastasis (TNM) staging classification system for lung cancer to the Union Internationale Contra Le Cancer (UICC) and to the American Joint Committee on Cancer (AJCC). We are now at work on the 8th revision, due in 2016, for which will be based on a combination of retrospective and prospective data collection. Similar efforts are also underway for malignant pleural mesothelioma and thymic malignancies, the latter with generous support from the Mesothelioma Applied Research Foundation.